Project Grant R43TR005424
Award Date
8/1/25
Completion Date
7/31/26
Dollars Obligated
$350K
Federal Agency
National Center for Advancing Translational Sciences
Federal Grant Program
93.350
Assistance Type
Project Grant
Place of Performance
California, USA
Similar Awards
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $350,000 to Cisterna Biologics, Inc. to develop a novel production and purification process for ultra-pure mRNA. The key objectives are to generate contaminant-free mRNA essential for high-dosage and frequent therapeutic applications, such as enzyme replacement and cancer immunotherapy. The approach involves developing...
The National Institute of General Medical Sciences (NIGMS) awarded a $300,518 Project Grant under CFDA Program 93.859 (Biomedical Research and Research Training) to E&E Bioclub LLC in Indianapolis, IN. The project aims to develop an all-in-one platform for intracellular overproduction of long, single-strand mRNA. This is intended to address challenges with current mRNA manufacturing methods, such as the cost and scalability constraints of in vitro transcription and the difficulty in...
This federal Project Grant award, valued at $419,398, was provided by the National Center for Advancing Translational Sciences (NCATS) under the CFDA Program 93.350 to accelerate the translation of oligonucleotide therapeutics by enhancing delivery. The project aims to develop a small molecule solution to improve the delivery of systemically administered oligonucleotide therapeutics to extrahepatic tissues, a critical unmet need that has limited the broad clinical translation of these...
The National Science Foundation (NSF) awarded a $274,980 SBIR Phase I Project Grant to Cisterna Biologics, Inc. to develop a novel platform for cost-efficient mRNA production in yeast. The project aims to transform yeast cells into efficient mRNA factories and utilize advanced chromatographic techniques for purification, with the goal of reducing mRNA manufacturing costs by 90% compared to current in vitro transcription methods. Key technical objectives include demonstrating stable mRNA fusion...
This federal Project Grant award of $324,998 from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) program supports Rejuvenation Technologies Inc. (RTI) in developing advanced therapeutic technologies for in vivo delivery of mRNA to stem and progenitor cells. The key objectives of this award are to: 1) generate a library of rationally designed peptides for targeting three progenitor cell types, 2) utilize computational...
The National Center for Advancing Translational Sciences (NCATS), under the CFDA Program 93.350, awarded a $338,997 Project Grant to Mabswitch Inc. effective January 1, 2024 to December 31, 2024. The project aims to develop "LENTISAFE LIGANDS: MILD-ELUTION IMMUNOAFFINITY LIGANDS FOR ENRICHMENT AND PURIFICATION OF LENTIVIRAL VECTORS." The goal is to create switchable affinity ligands that can be used to selectively isolate and enrich functional lentiviral vectors from production...
The National Institute of General Medical Sciences (NIGMS) awarded a $305,892 Project Grant under the Biomedical Research and Research Training program (CFDA 93.859) to Dotquant LLC, a biotechnology research and development company, to develop a new in vitro transcription kit for high-yield synthesis of chemically modified RNA. The project aims to combine the benefits of wild-type T7 RNA polymerase, which has high efficiency and low cost, with the ability of mutant T7 RNA polymerases to...
This Project Grant award from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859) provides $302,605.00 to Chimerna Therapeutics, Inc. to develop a scalable and low-cost method for semi-synthesis of site-specifically labeled circular RNAs (circRNAs). The goal is to improve the endosomal escape of RNA therapeutics by conjugating circRNAs with lipids to facilitate their delivery and therapeutic effect. The project aims...
This Project Grant award from the National Center for Advancing Translational Sciences (CFDA 93.350) provides $317,029 in funding to Chemia Biosciences, Inc., a small disadvantaged business, to develop advanced computational methods and software tools for discovering novel antimicrobial natural products. The project aims to leverage high-throughput mass spectrometry and genome mining techniques to identify new polysaccharides and aminoglycosides, a class of antibiotics, to address the growing...
This Project Grant award, valued at $936,000.00, was provided by the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training (CFDA 93.859) federal grant program. The goal of this project is to develop a platform called mRNADesigner, an integrated deep learning model to optimize the 5'UTR, codon usage, and 3'UTR of mRNA sequences simultaneously. This will enable users to design optimal mRNA sequences to enhance protein expression levels and...